These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35634804)

  • 1. Half-dose versus full-dose 18 F-FDG total-body PET/CT in patients with colorectal cancer.
    Tan H; Mao W; Cao Y; Cai D; Sui X; Qi C; Yu H; Zhang Y; Shi H
    Nucl Med Commun; 2022 Aug; 43(8):928-936. PubMed ID: 35634804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience.
    Tan H; Cai D; Sui X; Qi C; Mao W; Zhang Y; Liu G; Yu H; Chen S; Hu P; Gu J; Shi H
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1002-1011. PubMed ID: 34462790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer.
    Tan H; Sui X; Yin H; Yu H; Gu Y; Chen S; Hu P; Mao W; Shi H
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1966-1975. PubMed ID: 33244618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head intra-individual comparison of total-body 2-[
    Chen X; Hu P; Yu H; Tan H; He Y; Cao S; Zhou Y; Shi H
    Eur Radiol; 2023 Nov; 33(11):7890-7898. PubMed ID: 37338551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the quarter-dose 18 F-FDG total-body PET in routine clinical practice and its clinical value.
    Zhao M; Zan K; Cui X; Chai L; Ge M; Cheng Z; Sun H; Duan Y
    Nucl Med Commun; 2023 Dec; 44(12):1176-1183. PubMed ID: 37901913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pediatric malignancies using total-body PET/CT with half-dose [
    Chen W; Liu L; Li Y; Li S; Li Z; Zhang W; Zhang X; Wu R; Hu D; Sun H; Zhou Y; Fan W; Zhao Y; Zhang Y; Hu Y
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4145-4155. PubMed ID: 35788704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low
    Hu Y; Liu G; Yu H; Wang Y; Li C; Tan H; Chen S; Gu J; Shi H
    J Nucl Med; 2022 Jun; 63(6):959-965. PubMed ID: 34593593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultralow-dose [
    Tan H; Qi C; Cao Y; Cai D; Mao W; Yu H; Sui X; Liu G; Shi H
    Eur Radiol; 2023 Jul; 33(7):5017-5027. PubMed ID: 36688971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the long axial field-of-view PET/CT with low-dose [
    Sachpekidis C; Pan L; Kopp-Schneider A; Weru V; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1158-1167. PubMed ID: 36474125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose.
    Masuda Y; Kondo C; Matsuo Y; Uetani M; Kusakabe K
    J Nucl Med; 2009 Jun; 50(6):844-8. PubMed ID: 19443586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different hydration protocols for the quantification of healthy tissue uptake of half-dose
    Cao Y; Cai D; Sui X; Wang X; Song J; Tan H; Hu P; Zhang Y; Yu H; Shi H
    Quant Imaging Med Surg; 2023 Sep; 13(9):5701-5712. PubMed ID: 37711806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of acquisitions using total-body PET/CT with a half-dose [
    Chen Z; Wang Y; Yang X; Li L; Huo Y; Yu X; Xiao X; Zhang C; Chen Y; Zhao H; Zhou Y; Huang G; Liu J; Chen R
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3961-3969. PubMed ID: 37535107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image quality and lesion detectability in low-dose pediatric
    Zhao YM; Li YH; Chen T; Zhang WG; Wang LH; Feng J; Li C; Zhang X; Fan W; Hu YY
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3378-3385. PubMed ID: 33738519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of total-body
    Hu Y; Liu G; Yu H; Gu J; Shi H
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3538-3546. PubMed ID: 35344063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose
    He Y; Gu Y; Yu H; Wu B; Wang S; Tan H; Cao Y; Chen S; Sui X; Zhang Y; Shi H
    EJNMMI Phys; 2022 Jul; 9(1):45. PubMed ID: 35802280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [
    Mingels C; Spencer BA; Nalbant H; Omidvari N; Rokni M; Rominger A; Sen F; Cherry SR; Badawi RD; Abdelhafez YG; Nardo L
    J Nucl Med; 2024 Jul; 65(7):1101-1106. PubMed ID: 38664017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined whole-body dynamic and static PET/CT with low-dose [
    Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exploration of the feasibility and clinical value of half-dose 5-h total-body
    Adili D; Cai D; Wu B; Yu H; Gu Y; Zhang Y; Shi H
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2375-2385. PubMed ID: 36864361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.